The endothelin axis, comprising endothelin-1 (ET-1) and its receptors (ETA and ETB), is involved in the pathophysiology of different human tumors. Here we review conventional approaches and gene expression profiling indicating the association of ET-1 and its cognate receptors with human and rat leiomyomas, the most common benign tumors of myometrium. Specifically, ET-1/ETA interactions affect human and rat leiomyoma cell proliferation through protein kinase C and mitogen-activated protein kinase-dependent signaling pathways. Recent experiments demonstrate that the ET-1 axis exerts a potent antiapoptotic effect involving sphingolipid metabolism and prostaglandin-endoperoxide synthase 2/prostaglandin system in the rat Eker leiomyoma tumor-derived ELT3 cell line. Evidence supports that steroid hormones, growth factors, and extracellular matrix are key regulators of the leiomyoma growth. Interestingly, the ET-1 axis is under steroid hormones and can cooperate with these growth factors. Therefore, ET-1 alone or in association with these factors could contribute to the complex regulation of uterine tumor growth, such as proliferation, survival, and extracellular matrix production. This review summarizes current knowledge and emerging data on ET-1 in uterine leiomyoma pathology. endothelin signal, pathophysiology, tumor growth, uterine leiomyoma
INTRODUCTION
Uterine leiomyomas are the most common benign tumors that develop within the muscular layer of the uterus in up to 70% of reproductive-age women [1] . Chromosomal abnormalities are found in up to 40% of leiomyomas, with several common rearrangements predominating [2] . Several predisposing factors have also been identified, including age, ethnicity, nulliparity, family history, and obesity (for review: [2] [3] [4] ). Leiomyomas differ by their mass and location, and the presence of symptomatic leiomyomas due to pelvic pressure, uterine bleeding, and pain. They may be managed with medical therapy, but they remain the primary indication for hysterectomy [1] . Traditionally, estrogen has been considered as the major promoter of leiomyoma growth, but clinical observations also indicate that progesterone plays a critical role in the pathogenesis of leiomyomas [5] . Furthermore, the tumors regress after treatment with GnRH agonists, which create a hypoestrogenic state [6, 7] . This treatment has proven effective in causing leiomyoma regression, but with side effects that limit therapy [8] . Leiomyoma growth and apoptosis are regulated by a complex interplay of genomic and nongenomic signaling mechanisms of ovarian steroids. Indeed, estrogen and progesterone act indirectly via the production of growth factors, such as transforming growth factor (TGF) b, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), and insulin-like growth factor (IGF) 1 and 2 that have been involved in uterine leiomyoma formation (for review: [4, 9, 10] ). Activin and myostatin, two growth factors belonging to the TGFb family, also act in concert with steroid hormones to regulate leiomyoma growth (for review: [10] ).
Besides increased cell proliferation, leiomyomas, also called fibroids, are stiff tumors characterized by an excessive deposition of extracellular matrix (ECM) components, particularly collagen I, III, and IV, proteoglycans, and fibronectin [11] [12] [13] [14] [15] , and by an abnormal collagen fibril structure and orientation relative to adjacent myometrium [16, 17] . ECM proteins provide much more than just mechanical and structural support, as they regulate cell shape, proliferation, and differentiation [18] . ECM proteins are also able to serve as a reservoir for cytokines, inflammatory mediators, and growth factors, which affect tumor cell behavior (for review: [19] ). The turnover of the ECM is regulated by a balance between the action of membrane metalloproteases (MMPs), which degrade ECM, and their tissue inhibitors (TIMPs) [18, 20] . MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 were shown to be expressed in leiomyomas [21, 22] . Several studies report excessive production of profibrotic cytokines, including TGFb1 and TGFb3, and decreased or disrupted MMP activities [23, 24] . The expression of MMP and TIMP is also regulated by steroid hormones [25] , and GnRH agonist-induced leiomyoma regression is accompanied by an increase in MMP expression and a concomitant decrease in TIMP-1 expression, leading to an environment favoring ECM degradation [21] .
Among the hormones that regulate uterine functions and may have a role in the pathogenesis of leiomyomas, a good candidate is the peptidic growth hormone endothelin-1 (ET-1).
To date, several reports support the physiological role for ET-1 axis in the female reproductive tract, such as the ovarian and oviductal functions [26] , the endometrial functions during menstrual cycle [27] , and the implantation process [28] . In addition to its involvement in the pathogenesis of preeclampsia [29] , breast, ovarian, and cervical cancers [30] , the so-called ''ET-1 axis'' is associated with myometrial dysfunctions, such as premature uterine contractions [31] . ET-1 has attracted considerable attention when it was found in the uterus because of its regulatory role in the contraction process and the hypertrophy of myometrium during pregnancy (for review: [32] ). Thus, accumulated evidence supports the view that the ET-1 system is important in normal and pathologic uterus, where this peptide regulates pleiotropic cell functions (motility, proliferation, cell survival, etc.). The present Minireview summarizes recent data updates on the pathophysiological roles of the ET-1 system and its possible concerted actions with uterine leiomyoma growth environment.
THE ET AXIS
This axis comprises ET, ET receptors (ETRs), and ETRrelated G protein signaling. The past 3 decades have seen the emergence of a new potent vasoconstrictor, ET-1, that was first isolated from the supernatant of porcine aortic endothelial cell culture [33] . Since its discovery, the ET-1 system has been shown to affect a wide range of physiological (vascular tone, neurotransmission, tissue differentiation, immune response, glucose and lipid metabolism, smooth muscle contraction, development, cell proliferation, etc.) as well as pathological (cardiovascular disorders, pulmonary diseases, renal disorders, central nervous diseases, abnormal development, diabetes, and cancers) processes. Importantly, ETs participate in a wide range of processes related to cancer progression, such as cell proliferation, inhibition of apoptosis, inflammation, matrix remodeling, and metastasis ( Fig. 1) . Therefore, the ET-1 axis constitutes a potential therapeutic target for clinical medicine related to these tumor-associated processes. Interest in this area has been covered by excellent reviews [34] [35] [36] [37] .
ET-1 STRUCTURE
ET-1 is a cyclic peptide consisting of 21 amino acid residues, with two disulfide bridges connecting the cysteine amino acids (positions 1-15 and 3-11) at the N-terminal end and hydrophobic amino acids at the C-terminal end of the peptide. The C-terminal hydrophobic conserved sequence of ETs binds to the ETRs, and the N-terminal variable region determines the binding affinity to the receptors [33, 38, 39] . ET-1 belongs to ET family (ET-1, ET-2, and ET-3) and differs from ET-2 and ET-3 by 2 and 6 amino acids, respectively [40] . The human EDN-1 (ET-1 gene) is located on chromosome 6, EDN-2 on chromosome 1, and EDN-3 on chromosome 20 [41] .
ET-1 SYNTHESIS AND DEGRADATION
All three ETs are produced primarily as large precursor molecules, prepro-ETs, which undergo sequential proteolytic cleavages at dibasic sites by a furin-like endopeptidase to form big ETs (Fig. 1) . These biologically inactive intermediates are then cleaved between Trp21 and Val22 by two ET-converting enzymes (ECEs), ECE-1 and ECE-2, members of the membrane-bound zinc-binding metalloprotease family, to generate the mature ET peptides (for review: [42] ). Both ECE-1 and ECE-2 show preference for big ET-1 over big ET-2 or big ET-3. Because mice lacking ECE-1 and ECE-2 produce mature ET-1, an independent pathway involving chymase and non-ECE metalloproteinase has been suggested [43] . ET-1, the most widely expressed isoform and the best characterized, is not stored, but is secreted by constitutive or regulated pathways, depending on the cell type. Initially, ET-1 was considered to be of endothelial origin, but it now appears that ET-1 is synthesized and released from vascular and nonvascular cell types, including uterine smooth muscle cells (reviews: [36, 44, 45] ).
ET-1 level is also regulated by the degradation process. Indeed, ET-1 has a short half-life because it is rapidly degraded by neprilysin, a neutral endopeptidase, or is reduced by the clearance process mediated by ET-B receptor endocytosis and subsequent degradation in lysosomes [30] .
REGULATION OF ET-1 BIOSYNTHESIS
Prepro-ETs are synthesized via transcriptional activation of the prepro-ET gene, which is regulated by c-fos, c-jun, nuclear factor-1, activator protein-1, and GATA protein binding-2 [46] . Prepro-EDN-1 gene expression is regulated by multiple extracellular signals, including steroids, aldosterone, TGFb, leptin, insulin, cytokines (for review: [47] ), as well as by mechanical factors, such as shear stress [48] . This regulation occurs through different partners of signaling pathways. Indeed, the expression of prepro-ET-1 mRNA is regulated by phospholipase (PL) C/protein kinase C (PKC)/Ca 2þ signaling pathway [49] , Rho A [50] and mitogen-activated PK (MAPK) (for review: [47] ). By contrast, ET-1 synthesis can be retroinhibited at the prepro-ET-1 transcriptional level by nitric oxide production and decrease expression of ECE-1 through mRNA destabilization [51] .
The level of ET-1 mRNA is also regulated by posttranscriptional modifications via interacting proteins, such as glyceraldehyde 3-phosphate dehydrogenase, AU-binding factor, and micro-RNA (miRNA) [52] . Extracellular, cytoplasmic, and nuclear mechanisms involved in the regulation of EDN-1 promoter have been recently reviewed [47] .
ET RECEPTORS
ETs exert their functions through two receptor subtypes belonging to the G protein-coupled receptor family that have been cloned and classified as the ETA receptor and the ETB receptor [53, 54] . These receptors display different ligand selectivity. The ETA subtype has a higher affinity for ET-1 and ET-2 than for ET-3 [55] , whereas the ETB subtype does not discriminate between the three peptides, but binds specifically sarafotoxin 6c, a peptide extract from the venom of Atractaspis engaddensis [56] . Differences in the C-terminal sequences of both receptors affect G protein coupling, leading to multiple intracellular effects induced by ET-1. ETA and ETB can be coexpressed in the same tissue or the same cell, and experimental data demonstrate that ETA and ETB can exist as heterodimers [57] . Traditionally, ETA receptors are considered to be highly expressed in vascular smooth muscle cells [55] , whereas ETB receptors are mostly found in the endothelial cells [58] . Cumulative evidence also supports that ETA and ETB receptors are differentially expressed in a variety of cell types and organ systems throughout the body, including the female genital tract (for review: [59] ). The different tissue expression of the ETR subtypes is dynamic, and contributes to the different actions of the three ETs.
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ETR-RELATED G PROTEIN SIGNALING
ETR activation leads to various cellular functions through complex signaling pathways involving different G heterotrimeric and monomeric proteins that regulate the activity of numerous signaling enzymes and ion channels (Fig. 1 ). ET-1 activates different PLs (PLA2, PLC, and PLD). Among the most classical pathways is the activation of PLCb [60, 61] , leading to the formation of inositol 1,4,5 trisphosphate, which releases Ca 2þ from intracellular stores, and diacylglycerol stimulating PKC in myometrium. The Ca 2þ mobilization and PKC activation function synergistically in uterine smooth muscle cells to promote contractions [62] [63] [64] . In rat myometrium, the activation of PLC/PKC/calcium pathway by ET-1 results in the increase of PLD activity and subsequent acid phosphatidic production [65] . The contribution of PLD in ET-1-mediated myometrial contraction remains unknown. In addition, ET-1 has been shown to stimulate arachidonic acid production via PLA2 activation, leading to prostaglandin synthesis via prostaglandin-endoperoxide synthase 2 (PTGS2) (also known as cylo-oxygenase 2) activity in vascular smooth muscle [66, 67] . Some protein tyrosine kinases are activated by ET-1, such as Src in myometrium [68] and proline-rich tyrosine kinase 2 in vascular smooth muscle [69] . Different signaling pathways triggered by ET-1 converge to the classical activation of MAPK cascade (ras/raf/MEK/MAPK) for stimulating transcription of proto-oncogenes, such as c-fos, c-myc, and c-jun, in turn activating cell growth in human tumors (for review: [70, 71] ) and in rat myometrium [68] .
In addition, ET-1 activates different lipid kinases and enzymes involved in the production of other bioactive lipid mediators (Fig. 1) . Indeed, ET-1 stimulates phosphoinositide 3-kinase (PI3K) in different cell types [37, 71] , including rat myometrial cells [68] . Subsequently, phosphatidylinositol 3,4,5-triphosphate may act as a lipid second messenger, promulgating signals via a high-affinity interaction with pleckstrin homology domains in downstream effectors, such as phosphoinositide-dependent PK-1 and mammalian target of rapamycin (mTOR), to regulate cell proliferation [37, 71, 72] . Furthermore, in myometrial tissues, the activation of PKC by ET-1 leads to an increase of sphingosine kinase1 (SphK1) activity and subsequent stimulation of RhoA/Rho-kinase FIG. 1. ET-1 synthesis, signaling partners, and functions. ET-1 is produced as prepro-ET-1, cleaved by furin protease to obtain Big ET-1 that is proteolyzed by ECE to produce the active form of ET-1. ET-1 binds to ETRs coupled to different G proteins involved in the regulation of several effectors implicated in the activation of protein and lipid kinases. ET-1 is a peptidic hormone that regulates multiple functions, including proliferation, cell survival, contraction, and differentiation involved in physiology and disease. ERK, extracellular signal-regulated kinase; FAK, focal adhesion kinase; JUNK, c-Jun N-terminal kinase; MEK, MAPK kinase; Rho K, Ras homology kinase; RTK, receptor tyrosine kinase.
ENDOTHELIN AND LEIOMYOMA pathway that facilitates myometrial contraction [63] . Additionally, ET-1 drives multiple signaling pathways to potentiate the function of other growth factors, such as EGF, IGF, or TGFb via their receptor transactivation [69, [73] [74] [75] [76] .
ET-1: A GROWTH FACTOR IN LEIOMYOMA
Factors responsible for the abnormal proliferation of myometrial cells that accompanies leiomyoma formation remain poorly characterized, although steroid hormones and several peptide growth factors, such as EGF, IGF and plateletderived growth factor (PDGF), have been implicated [8, 9] . Attention has been drawn to the possibility that ET-1 might be a promoter of myometrial cell growth, because this peptide may be involved in the development of a variety of neoplasms, acting in an autocrine/paracrine fashion during tumor development and metastasis [35, 37, 71] .
ET-1 mRNA is upregulated in human leiomyomas [44, 45] . That ET-1 has growth-promoting properties in uterine tumors is supported by the presence of ETA receptors functionally coupled to PLC pathway activation in leiomyomas [45, 77] . Only these ETA receptors are involved in the mitogenic effect of ET-1 in cultured human myometrial cells [78] , although mRNA for both ETA and ETB has been detected. In humans, ETA expression is predominant in leiomyomas relative to matched normal myometrium, as reported by gene array [79] . This is logical for a tissue that originates from a uterine smooth muscle cell that predominantly expressed ETA receptors [45, 77, 79] , and might reflect an increased estrogen responsiveness, since estrogen was reported to induce an upregulation of myometrial ETA receptors [80] .
Substantial evidence indicates that the PKC signaling pathway is required for ET-1-induced human leiomyomas and myometrial cell growth in response to growth factors. After stimulation with ET-1, differential pattern of redistribution/ activation of conventional (c), novel (n), and atypical (a) PKC isoforms occurs in leiomyoma and myometrium, suggesting a selective role of PKC isoforms in cell proliferation [81] . Interestingly, the level of PKCb is upregulated in human leiomyoma [82] . PKCa has important functions in myometrium, as it is involved in ET-1-induced MAPK activation and growth in human and rat uterine smooth muscle cells [62, 68, 83] . Cellular functions associated with activation of this PKC isoform include proliferation and inhibition of apoptosis. It was shown that estrogen can rapidly alter these signaling pathways in leiomyoma cells [84] . To date, it remains to be determined if ET-1 may facilitate human uterine leiomyoma growth by a combined function modulating both cellular proliferation and cell death.
Tumor-derived cell line from Eker rat leiomyomas (ELT3) has been developed as an in vitro model to investigate the mechanisms involved in leiomyoma pathogenesis [85] . As in human leiomyoma, ELT3 cell proliferation rate is increased by steroid hormones and growth factors acting via receptor tyrosine kinases, but also by peptidic hormones, such as ET-1. Indeed, ET-1-mediates cell proliferation in ELT3 cells, and this effect is more pronounced than in normal myometrial cells [86, 87] . The mitogenic effect of ET-1 is associated with coexpression of ETA and ETB that are upregulated in terms of mRNA, ET-1 binding capacity, and coupling to signaling pathways in ELT3 cells [86] . The upregulation of ETA is consistent with previous reports demonstrating ETA overexpression in human leiomyomas [44, 45, 77, 79] and in steroiddependent tumors, such as prostate, ovary, or breast cancers [30, 71] . The growth properties of ET-1 depend on the MAPK signaling pathway. In both myometrial and leiomyoma cell models, ET-1 activates PLC and PLD pathways (Fig. 2) . However, in leiomyoma cells, but not in normal myometrial cells, PLD contributes to MAPK3/1 (commonly termed ERK1/ 2) activation and subsequent cell proliferation [87] . In rat normal myometrial cells, ET-1/ETA axis induces DNA synthesis through the activation of both the Gq/PLCb/c/nPKC and Gi/PI3K/aPKC pathways. These two signaling pathways converge to the activation of Src tyrosine kinase and subsequent MAPK3/1 activation [68] . In leiomyoma cells, ETA and ETB contribute to the activation of MAPK3/1 via PLCb/PKC/PLD cascade. The activation of MAPK 3/1 and cell proliferation mediated by ET-1 are PI3K independent. Although ET-1 can transactivate growth factor receptors in various cell types [71] , ET-1 does not transactivate EGF receptor or PDGF receptor in rat myometrial cells [68] and ELT3 leiomyoma cells (P. Robin, personal communication).
ET-1: A SURVIVAL FACTOR IN LEIOMYOMA
In addition to inducing proliferative effects, ET-1 acts as an antiapoptotic factor in ELT3 cells, indicating that the peptide modulates cell survival pathways (Fig. 2) . Indeed, in leiomyoma cells, but not in myometrial cells, ET-1 induces cell survival through the contribution of a SphK1-dependent mechanism [88] . ELT3 leiomyoma cells, like rat myometrium at late gestation [89] , are able to release sphingosine 1 phosphate (S1P) in the medium via the ABCC1 transporter (ATP binding cassette, subfamily C, member 1), subsequent to the activation of SphK1, PKC, and MAPK3/1 [90] . Furthermore, in leiomyoma cells, but not in normal myometrial cells, ET-1 activates MAPK14 (p38) independently from MAPK3/1. MAPK14 cooperates with MAPK3/1 to regulate ET-1-mediated survival of ELT3 cells via the induction and activation of PTGS2 and subsequent production of prostaglandin E2 (PGE2). These data (Fig. 2) suggest that the PTGS2/ PGE2 axis could play an important role in leiomyoma growth [91] .
Interestingly, these cumulative findings reveal that ET-1 triggers differential signaling pathways in leiomyoma compared to myometrial cells (Fig. 2) . In particular, the activation of p38 by ET-1 in ELT3, but not in myometrial cells, may be relevant. It has been reported that the level of p38 expression [92] and activity [18] are upregulated in human leiomyoma compared to matched myometrial tissues. The p38 MAPK family consists of four isoforms (p38a, p38b, p38c, and p38d), but the function of each p38 isoform in leiomyoma remains to be identified. The specific activation of p38 in leiomyoma cells can be consequent to the upregulation of ETRs found in these cells. Such upregulation supports the appearance of new signaling pathways associated with novel functions for ET-1 [93] . The differences in the mechanism of MAPK activation by ET-1 can also be explained by an oligomerization of ETA and ETB in rat leiomyoma cells [86] , or by the downregulation of dual specific phosphatases, that dephosphorylate MAPK, previously reported in human leiomyoma [12] .
MAPK p38 (MAPK14) is one of the Rho A effectors. Recent data reported that p38 phosphorylation was greater in leiomyoma in comparison with matched myometrium. This increase is associated with upregulation of Rho-GEF [18] and Rho A activity [17] . Recent data indicate that the upregulation of Rho/p38 pathway in human leiomyoma plays an important role in mechanotransduction linked to the increase of the environment stiffness [18, 23] . In myometrium, RhoA contributes to ET-1-mediated myometrial contraction [63, 94] . However, the upregulation of RhoA observed in human leiomyoma cannot be related to the contraction in as much as TANFIN AND BREUILLER-FOUCHÉ leiomyoma does not contract in response to ET-1, as tested by in vitro contractile studies (Breuiller-Fouché, unpublished results]. RhoA is involved in the regulation of ET-1 synthesis [47, 95] . Therefore, more studies are needed to understand the role of RhoA/p38 in leiomyoma and the importance of a possible positive loop between ET-1 and RhoA in the leiomyoma growth process.
POTENTIAL ET-1 INTERACTIONS IN THE COMPLEX PROCESS OF LEIOMYOMA GROWTH
Data summarized above indicate that ET-1 can act alone, but this peptidic growth factor can also be considered as one important part of the complex network that coordinates multiple functions involved in leiomyoma development (Fig.  3) . The tissue fibrotic state is due to the aberrant accumulation of ECM subsequent to the alteration of the MMP/TIMP balance [15, 16, 21, 22 ]. An upregulation of ECM, which is characterized by an increase in collagen biosynthesis and a decrease in collagen breakdown, has been reported in leiomyomas [24] . An abnormal collagen fibril structure and orientation has also been evidenced in leiomyomas [16] .
Growth factors are likely candidates to promote collagen biosynthesis and enlarge the volume of uterine tumor [10, 11] . Thus, it is expected that ET-1 contributes to the uterine tumor growth, since this peptide is able to increase the net balance of MMP/TIMP and, secondarily, to cause a rapid degradation of the ECM [71] . For example, MMP expression is regulated by ET-1 in myometrium [96] . In addition, ET-1 may contribute to the ability of TGFb, the principal mediator of leiomyoma fibrosis and growth [11, 15, 16, 97] , to promote a profibrotic phenotype. An upregulation of ECE by TGFb has been reported [98] . Such TGFb/ET-1 interaction may be facilitated by the upregulation of ECM molecules that serve to confine different growth factors in the proximity of tumor [11, 15] . Therefore, considering the wide range of profibrotic activity of ET-1 in different pathologies, one could expect that ET-1 alone or in coordination with TGFb, steroid hormones, and/or associated growth factors receptors with intrinsic tyrosine kinase activity, such as EGF and IGF receptors, may contribute to the increase of leiomyoma fibrotic state [10, 11] .
A recent review summarized cumulative evidence supporting the implication of inflammatory-related mediators in leiomyoma pathology. The fibrotic tissue environment con-FIG. 2. Differential signaling pathways triggered by ET-1 in leiomyoma and normal myometrial cells. Compared to normal myometrial cells, leiomyoma cells express both ETA and ETB involved in the activation of PLC and PLD that contribute to the activation of MAPK3/1 (ERK1/2) and subsequent cell proliferation. In leiomyoma, ET-1-induced cell proliferation is more important than in normal myometrial cells. In addition, ET-1 activates MAPK14 (p38), which cooperates with MAPK3/1 to induce cyclooxygenase2 (PTGS2) and PGE2 production. PGE2 and the activation of sphingosine kinase pathway are involved in ET-1-mediated cell survival.
ENDOTHELIN AND LEIOMYOMA centrates various growth factors, cytokines, and chemokines able to act in a paracrine and/or autocrine manner to maintain the inflammatory characteristics of uterine tumor [11] . ET-1 is an important stimulus for inflammation in both innate and adaptive immunity. Recent data demonstrate that inflammatory stimulus via TLR7 activates ET1/ETR axis, leading to the increase of TGFb production and subsequent fibrosis [99] . Furthermore, prostaglandins and S1P are recognized as proinflammatory mediators [11, 100] , and their production is enhanced by ET-1 in many cell types, including leiomyoma cells [88, 91] . Based on these ET-1 properties, it is tempting to propose this peptide as a proinflammatory mediator in leiomyoma pathology. Further investigation is needed to confirm this hypothesis.
The link between inflammation/fibrosis and cell transformation has long been suspected [11] . Leiomyomas are believed to originate from the transformation of smooth muscle cells under the control of ovarian steroids and proinflammatory and profibrotic mediators. As reported above, TGFb3 is a critical determinant in several remodeling diseases, including leiomyomas [11, 15, 16, 97] , and a connection between TGFb and ET-1 is well established [75, 98] . Additionally, ET-1 promotes epithelial-to-mesenchymal transition in ovarian cancer cells [74] . As such, it cannot be excluded that ET-1 may contribute to the phenotypic myofibroblast differentiation during uterine tumor growth. Stem cells detected in human myometrium can be differentiated into leiomyoma cells, and, so far, only one estrogen-and hypoxia-dependent mechanism has been reported [101] . The role of ET-1 in this process is yet to be proven.
An elegant experimental in vitro coculture model has demonstrated that human uterine leiomyoma-derived fibroblasts stimulate human leiomyoma cell proliferation and enhance the production of ECM proteins [102] . The leiomyoma growth may be mediated, in part, by autocrine and/or paracrine mechanisms that promote the synthesis of growth factors. Interestingly, leiomyoma cells express TGFb receptors and Smads and overexpress TGFb relative to normal myometrium [10] . ET-1 has yet to be identified as a soluble factor released by these tumor-derived fibroblasts and/or leiomyoma cells to stimulate the proliferation of leiomyoma cells and enhance the production of ECM. TGFb can utilize a multitude of intracellular signaling pathways in addition to FIG. 3 . Schematic integration of ET-1 as a growth factor regulating the complex network involved in leiomyoma growth. ET-1 regulates leiomyoma growth alone or by coordinated mechanisms with steroids, TGFb, EGF, PDGF, IGF, and VEGF, the well-known factors associated with leiomyoma pathology. Steroid hormones may impact the expression of miRNAs that control the level of growth factors, including ET-1. The increase of ECM proteins related to leiomyoma is linked to mechanical signaling that may control ET-1 synthesis and tumor growth. All these factors emerging in leiomyoma pathology activate MAPK-dependent and -independent signaling pathways (such as the Akt/PI3K/mTOR pathway) for regulating a diverse range of functions (proliferation, survival, inflammation, angiogenesis, ECM deposition, etc.) involved in leiomyoma formation. A direct relationship between ET-I and these functions is well established in tumor growth, but not yet in leiomyoma (dashed arrows).
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Smads to regulate a wide array of functions, such as PI3K/ AKT/mTOR [103] . The mTOR pathway is one of the most highly upregulated pathways in leiomyoma from both rat and human [104] . Establishing a link between ET-1 and mTOR in leiomyoma may help in identifying new targets.
The research results of the past 2 yr have emphasized the role of micro-RNAs (mi-R) as key regulators of cell transformation and tumorigenesis (review: [105] ). Thus, miR-21 was found to be overexpressed in leiomyoma when compared to myometrium, and was regulated by steroid hormones and the TGFb signaling pathway [106] . Elucidation of the role of miRNAs in leiomyoma and their potential impact on the ET-1 axis warrant further investigation.
Angiogenesis is essential for the regulation of tumor growth. This process of neovascularization is regulated by hypoxia, which triggers the increased expression of various endothelial growth factors and/or receptors. Thus, ET-1 could modulate tumor angiogenesis, acting directly on endothelial cells via the ETB receptors and, in part, via activation of the ET-1/ETA receptor axis through the induction of proangiogenic factors [107] . In ovarian carcinoma cells, ET-1 via ETA induces vascular endothelial growth factor (VEGF) by increasing hypoxia-inducible factor-1 [108] . In human leiomyomas, ETA receptors are overexpressed [44, 45, 77, 79] as they are adrenomodulin, bFGF, and VEGF the most likely candidates to promote angiogenesis [11, 109] . This could explain the higher vascular density and endothelial proliferative index observed in leiomyomas compared to the normal myometrium [109] . By contrast, a reduced microvessel density was observed in uterine leiomyoma compared with adjacent myometrium [79] . The contribution of the ET-1 axis in this apparent controversial angiogenesis process within leiomyomas has not yet been investigated.
FUTURE PERSPECTIVE
ET-1 has been known for more than 20 years to be a key player in a wide variety of biological processes, including differentiation, proliferation, survival, contraction, and angiogenesis. Several lines of evidence also support the involvement of ET-1 in obstetrics and gynecologic biology and disorders. Leiomyoma prevalence increases with obesity, and hypertension and cumulative data provide evidence that all these diseases are associated with an upregulation of ET level [36] . As outlined in the present review, the ET-1/ETA receptor pathway is involved in uterine leiomyoma growth, and experimental studies strongly indicate that ET-1 may be an additional growth factor that can be targeted in the clinical setting of uterine leiomyoma. The molecular diversification of the ET system implies different signaling pathways that may be interrupted at many levels (i.e., synthesis, receptor binding, or intracellular signaling; Fig. 1 ). In this respect, there are published works showing application of either highly selective antagonist ETA receptors [31, 71] or pharmacological inhibitors of ECE-1 to efficiently block delivery in a mouse model of preterm labor [110] . As outlined previously, experimental data provide evidence that the ET-1 axis contributes to leiomyoma growth in both animal and human models. Although the rat Eker model is not recognized by all scientists in the field, it remains the most useful animal model routinely used in research to study cellular and mechanisms encountered in human uterine tumor pathogenesis [111] . Interestingly, rat Eker-and ELT3-derived cells share many common properties with human leiomyoma, particularly steroid [104] and ET responsiveness. The important physiopathological aspects of the ET system need to be explored using diverse models that mimic human leiomyoma formation, ranging from the cell to the more integrated transgenic models. In vitro cell culture models of human leiomyomas exist, and have the advantages of being derived from human progenitor tissues, but may present classical phenotypic changes. Data from microarray studies indicate that culture conditions significantly alter the gene expression profile of both myometrial and leiomyoma cells, reducing differences between them in vitro compared with those in vivo [112] . No information is yet available on whether culture conditions of human leiomyoma cells affect the expression of ET-1 and ETR genes. The application of new models is required to advance translational research in leiomyomas. Of great interest are the immortalization of human leiomyoma cell lines after induction of telomerase [113] and the coculture system between uterine leiomyoma-derived fibroblasts and uterine leiomyoma cells to improve our understanding of cell processes involved in cellcell interactions in tumors [102] . Very recently, much attention has also been given to a three-dimensional (3D) culture system of leiomyoma cells. In this 3D model, the leiomyoma cells closely resemble the molecular phenotype of progenitor tissue architecture [114] . Xenograft models established by grafting human leiomyoma tissue in immunodeficient mice [115, 116] may offer an interesting alternative to understanding this disease.
Unraveling the whole cascade of ET-1 activation occurring in leiomyoma cells appears to be more complex in humans, especially because of the genetic variability between patients and distinct chromosomal alteration between tumors. Thus, it is largely accepted that leiomyomas within the same uterus may grow at different rates despite the identical exposure to hormonal milieu. Their growth are not influenced by size and location. Pregnancy is protective for leiomyoma development and their size do not predict growth rate. Significant ethnic differences in leiomyoma growth are also observed when age was considered, with tumor growth rates decline in white (but not in black) women as they age [117] . All these findings must be considered for future basic research on the ET system, and have implications for further therapeutic innovation. Future nonsurgical treatments of leiomyomas may thus include potential benefits of pharmacological compounds, such as ETA antagonist together with inhibitors of ECE-1. Such pharmacological strategies may avoid hysterectomy, which remains a frequent alternative when conservative treatment fails.
